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Abstract
Proteinuria and hyperphosphatemia are risk factors for cardiovascular disease in patients with
chronic kidney disease (CKD). Although the interaction between proteinuria and the serum
phosphate level is well established, the mechanistic link between the two, particularly the extent
to which this interaction is mediated by phosphate-regulating factors, remains poorly under-
stood. In this study, we examined the association between proteinuria and the serum phos-
phate level, as well as potential mediators, including circulating fibroblast growth factor
(FGF23)/klotho, the 24-h urinary phosphate excretion rate to glomerular filtration rate ratio (EP/
GFR), and the 24-h tubular phosphate reabsorption rate to GFR ratio (TRP/GFR). The analy-
ses were performed with data from 1793 patients in whom 24-h urine protein and phosphate,
serum phosphate, FGF23, and klotho levels were measured simultaneously, obtained from the
KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD). Mul-
tivariable linear regression and mediation analyses were performed. Total, direct, and indirect
effects were also estimated. Patients with high serum phosphate levels were found to be more
likely to exhibit greater proteinuria, higher FGF23 levels, and lower klotho levels. The 24-h EP/
GFR increased and the 24-h TRP/GFR decreased with increasing proteinuria and CKD pro-
gression. Simple mediation analyses showed that 15.4% and 67.9% of the relationship
between proteinuria and the serum phosphate level were mediated by the FGF23/klotho ratio
and 24-h EP/GFR, respectively. Together, these two factors accounted for 73.1% of the rela-
tionship between serum markers. These findings suggest that proteinuria increases the 24-h
EP/GFR via the FGF23/klotho axis as a compensatory mechanism for the increased phos-
phate burden well before the reduction in renal function is first seen.
PLOS ONE







Citation: Jung JY, Ro H, Chang JH, Kim AJ, Lee
HH, Han SH, et al. (2020) Mediation of the
relationship between proteinuria and serum
phosphate: Insight from the KNOW-CKD study.
PLoS ONE 15(6): e0235077. https://doi.org/
10.1371/journal.pone.0235077
Editor: Tatsuo Shimosawa, International University
of Health and Welfare, School of Medicine, JAPAN
Received: February 18, 2020
Accepted: June 7, 2020
Published: June 22, 2020
Copyright: © 2020 Jung et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its supporting information
files.
Funding: This work was supported by the
Research Program funded by the Korea Centers for




Competing interests: The authors have declared
that no competing interests exist.
Introduction
Patients with chronic kidney disease (CKD) exhibit significantly elevated rates of cardiovascu-
lar disease–related morbidity and mortality compared with the general population. Proteinuria
and hyperphosphatemia have been identified as important kidney-specific risk factors [1–4],
although the mechanistic links between these factors and disease outcomes remain poorly
understood.
Under normal conditions, proteins that pass through the glomerular filtration barrier are
captured in the proximal tubule and transferred to the systemic circulation; this process causes
proteinuria in patients with glomerular damage [5, 6]. Phosphate serves as a buffer to help
maintain normal serum levels as renal function decreases. As the glomerular filtration rate
(GFR) decreases, the serum phosphate concentration is maintained within a normal range via
the increased excretion of phosphate. Most of the phosphate that is filtered through the kidney
is regulated by sodium and phosphate cotransporters 2a and 2c (NaPi-2a and NaPi-2c), located
in the apical membrane of the renal proximal tubule, which is regulated by parathyroid hor-
mone (PTH) and fibroblast growth factor 23 (FGF23) [7].
A previous study showed that phosphate levels remain high, regardless of the GFR, in chil-
dren with nephrotic-range proteinuria [8]. Another study suggested that FGF23 modifies albu-
minuria as part of an off-target effect in patients with CKD and immunoglobulin A (IgA)
nephropathy [9]. In addition, klotho, a co-receptor of FGF23, was shown to inhibit excess
phosphate by interfering with tubular phosphate reabsorption of NaPi-2a [10, 11]. In CKD,
phosphate excretion rises as the GFR falls if the process is not accompanied by an influx of
phosphate into the systemic circulation (from intestinal absorption, redistribution, and other
circulation factors). At the same time, the tubular reabsorption of phosphate may also fall or
remain unchanged [12–15]. Kim et al. [16] recently reported that patients with CKD and pro-
teinuria >1.0 g/day exhibited higher serum phosphate levels and reduced FGF23 activity,
which may comprise a risk factor for CKD progression. In addition, Di Iorio et al. [17]
reported a potential important interaction by which phosphate interferes with the antiprotei-
nuric response in patients with very-low-protein diets; however, this observation remains con-
troversial, as other researchers have reported that use of a high-phosphate food additive did
not directly cause albuminuria [18].
As physiologically filtered phosphate is mostly reabsorbed, a further increase in reabsorp-
tion is not uncharacteristic. Phosphate reabsorption and excretion are reduced progressively
as renal function deteriorates in patients with CKD. Thus, potential causes of serum phosphate
elevation in patients with CKD and proteinuria need to be examined in detail, beyond the sim-
ple increase in reabsorption and/or decrease in excretion of phosphate. In this study, we fur-
ther analyzed the effect of proteinuria on renal phosphate regulation with consideration of
potential mediators.
To determine whether this assumption is clinically relevant, we performed a variety of anal-
yses to identify factors affecting the processing of renal phosphate. These analyses included
direct assessment of phosphate influx and its association with proteinuria and the serum phos-
phate level, as well as assessment of whether the association of proteinuria with the serum
phosphate level is influenced by potential mediators.
Materials and methods
Study design and participants
Data for this study were taken from the KoreaN cohort study for Outcome in patients With
Chronic Kidney Disease (KNOW-CKD; NCT01630486 at http://www.clinicaltrials.gov), a
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multicenter prospective study of a pre-dialysis cohort of 2238 patients with CKD conducted
from 2011 to 2016. More detailed overviews of the design and methods of the KNOW-CKD
study have been published previously [19].
Study inclusion was limited to patients for whom clinical data on 24-h urine protein and
phosphate levels, as well as serum phosphate, FGF23, and klotho levels, had been collected
simultaneously. All patients with missing values were removed from our analysis, resulting in
a final total of 1793 patients included in this analysis. This study was conducted in accordance
with the Declaration of Helsinki, and the research protocol was approved by the institutional
review boards of the Seoul National University Hospital (1104–089–359), Seoul National Uni-
versity Bundang Hospital (B-1106/129-008), Yonsei University Severance Hospital (4-2011-
0163), Kangbuk Samsung Medical Center (2011-01-076), Seoul St. Mary’s Hospital
(KC11OIMI0441), Gachon University Gil Medical Center (GIRBA2553), Eulji General Hospi-
tal (201105–01), Chonnam National University Hospital (CNUH-2011-092), and Pusan Paik
Hospital (11–091). Written informed consent was obtained from all subjects.
Variables
Data on patients’ sociodemographic characteristics, smoking status, medical histories, medica-
tion use, and health-related behaviors were collected using a self-administered questionnaire
with the assistance of trained staff. Blood samples were collected after fasting for at least 8 h.
Random midstream urine samples were collected using a standard protocol and sent to the
central laboratory of the KNOW-CKD study (Lab Genomics, Seongnam, Republic of Korea).
Serum creatinine levels were measured using traceable isotope dilution mass spectroscopy.
Estimated glomerular filtration rates (eGFRs) were calculated using the Chronic Kidney Dis-
ease Epidemiology Collaboration equation [20].
Measurements
Serum intact FGF23 and C-terminal fibroblast growth factor 23 (cFGF23) levels were mea-
sured using an enzyme-linked immunosorbent assay (ELISA; Immunopics, Inc., Athens, OH,
USA). The serum α-klotho level was measured using a commercially available ELISA kit
(Immuno Biological Laboratories Co., Ltd.).
The fractional excretion of phosphate (FEP) was defined as the ratio of phosphate clearance
to creatinine clearance: FEP (%) = (urine phosphate × serum creatinine) × 100 / (serum
phosphate × urine creatinine). To quantify the possible phosphate excretion and reabsorption
at the time of serum sampling for the measurement of phosphate, the 24-h excretion of phos-
phate (EP) was calculated using the formula: 24 h EP (mg/day) = 24-h urinary phosphate level
(mg/day). The 24-h tubular reabsorption rate of phosphate (TRP) was calculated using the for-
mula: 24 h TRP (mg/day) = 14.4 × GFR (mL/min) × serum phosphate (mg/dL)– 24-h EP (mg/
day). Those factors, corrected for the GFR, were reported as 24-h EP/GFR and 24-h TRP/GFR,
respectively.
The daily protein intake (DPI) was estimated using the 24-h urinary urea nitrogen (UUN)
level following Maroni et al. [21]: DPI (g/day) = 6.25 × (24-h UUN (g/day) + 0.031 (g/kg/day)
× ideal body weight (kg), where the ideal body weight was calculated assuming the optimal
body mass index (BMI) of 22.5 kg/m2 [22]. The DPI was expressed as the normalized esti-
mated DPI divided by ideal body weight (g/kg/day).
Statistical analysis
Normally distributed data are expressed as means ± standard deviations, and variables with
skewed distributions are expressed as medians (interquartile ranges). Categorical data are
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expressed as numbers (percentages). Differences between groups were analyzed using Stu-
dent’s t test, the Mann–Whitney U test, the chi-squared test, one-way analysis of variance, and
the Kruskal–Wallis test, as appropriate. To study the association between proteinuria and the
serum phosphate level, we performed stepwise multiple linear regression analyses. Proteinuria
is expressed as 24-h urinary protein excretion (UPE) in categories (<30, 30–300, 300–1000,
and�1000 mg/day). The DPI; high-sensitivity C-reactive protein (hsCRP), FGF23, and klotho
levels; and 24-h EP/GFR were natural log–transformed due to skewed distributions.
We performed mediation analyses with the PROCESS macro [version 3; model = 4, simple
mediator model (S1A Fig in S1 Data); model = 6, serial two-mediator model (S1B Fig in S1
Data)] and various measures of effect size for indirect, direct, and total effects, along with boot-
strapping with 10,000 resamples for confidence interval (CI) calculation using the method
described by Hayes [23]. All analyses were performed using IBM SPSS (version 23.0; IBM Cor-
poration, Armonk, NY, USA) and R (version 3.5.1; Vienna, Austria) software. Two-sided p
values� 0.05 were considered to be significant. To correct for multiple comparisons across
mediations, Bonferroni correction or bootstrapping were applied.
Results
Baseline characteristics
Data from a total of 1793 patients were analyzed by serum phosphate quartile. The mean age
of the patients was 54 years, and 60.2% of the participants were male. Other baseline character-
istics are listed in Table 1.
With increasing serum phosphate level, patients exhibited steady increases in the level of
FGF23 and the 24-h EP/GFR and 24-h TRP/GFR, combined with decreases in the klotho level
and DPI (Table 1).
Proteinuria, the FGF23/klotho ratio, the 24-h EP/GFR, and the serum
phosphate level
Table 2 shows crude and adjusted relationships between 24-h UPE and the serum phosphate
level. Coefficients (Coeff.) and standard errors (SEs) are expressed according to increasing
24-h UPE categories (<30, 30–300, 300–1000, and�1000 mg/day). The association between
proteinuria and the serum phosphate level was maintained well in the adjusted analysis relative
to the crude analysis (Coeff. ± SE, 0.153 ± 0.017; p< 0.001; Table 2) after controlling for age,
sex, smoking, BMI, diabetes mellitus (DM), hypertension (HTN), Charlson comorbidity index
(CCI), renin-angiotensin-aldosterone system blocker use, PTH level, DPI, hsCRP level, and
eGFR. In model 4, with the addition of the FGF23/klotho ratio and 24-h EP/GFR, the associa-
tion was no longer significant, as evidenced by a significant decrease in the correlation coeffi-
cient (Coeff. ± SE, 0.017 ± 0.022; p = 0.444; Table 2).
Serum phosphate levels were consistently higher among patients with more severe protein-
uria, reflecting CKD progression (Fig 1A). A similar trend was seen for the serum FGF23/
klotho ratio, which increased with the degree of proteinuria as CKD progressed (Fig 1B). A sig-
nificant decrease in the 24-h TRP/GFR and increase in the 24-h EP/GFR were also observed in
association with the proteinuria increase as CKD progressed (Fig 1C and 1D). We attempted
to determine the complexity of the relationship of changes in the FGF23/klotho ratio, 24-h
TRP/GFR, 24-h EP/GFR, and serum phosphate level to changes in proteinuria and renal func-
tion. The FGF23/klotho ratio, 24-h EP/GFR, and serum phosphate level increased steadily
over time, while the 24-h TRP/GFR decreased steadily (Fig 2A and 2B). As the GFR decreased,
the 24-h TRP/GFR decreased gradually and the 24-h EP/GFR increased significantly. These
PLOS ONE Proteinuria and serum phosphate
PLOS ONE | https://doi.org/10.1371/journal.pone.0235077 June 22, 2020 4 / 16
effects were seen earlier and occurred more rapidly in association with the severity of protein-
uria (Fig 2C and 2D). In contrast, no significant change in the 24-h EP/GFR was observed in
association with underlying diseases, including DM, HTN, and glomerulonephritis (S2 Fig in
S1 Data).
Table 1. Baseline characteristics of study subjects according to quartiles of serum phosphate.









Age, yr 54.0 ± 12.0 53.1 ± 12.4 54.4± 12.1 53.8 ± 11.9 54.5 ± 11.7 0.169
Male, n (%) 1079 (60.2) 350 (76.1%) 309 (69.8%) 223 (52.3%) 197 (42.5%) < 0.001
BMI, kg/m2 24.6 ± 3.4 24.5 ± 3.1 24.7 ± 3.1 24.7 ± 3.8 24.5 ± 3.6 0.879
Smoking, n (%) 842 (47.0) 260 (56.5%) 233 (52.7%) 178 (41.8%) 171 (36.9%) < 0.001
DM, n (%) 628 (35.0) 116 (25.2%) 129 (29.1%) 158 (37.1%) 225 (48.5%) < 0.001
HTN, n (%) 1724 (96.2) 442 (96.1%) 423 (95.5%) 405 (95.1%) 454 (97.8%) 0.140
CVD, n (%) 297 (16.6) 74 (16.1%) 79 (17.8%) 75 (17.6%) 69 (14.9%) 0.596
CCI 3.4 ± 2.2 3.1 ± 2.2 3.3 ± 2.2 3.4 ± 2.2 4.0 ± 2.2 < 0.001
GFR, ml/min/1.73m2 53.1 ± 30.8 61.9 ± 28.1 58.4 ± 29.0 55.0 ± 31.3 37.6 ± 28.8 < 0.001
24hr UPE, mg/day� 540.0 (168.0–
1566.6)
393.5 (133.6–928.4) 436.0 (132.9–1189.0) 567.2 (175.0–1670.0) 991.3 (319.8–2415.6) < 0.001
RAAS blockers, n (%) 1539 (85.8) 390 (84.8%) 386 (87.1%) 358 (84.0%) 405 (87.3%) 0.397
Diuretics, n (%) 574 (32.0) 98 (21.3%) 121 (27.3%) 137 (32.2%) 218 (47.0%) < 0.001
CCBs, n (%) 776 (43.3) 173 (37.6%) 178 (40.2%) 172 (40.4%) 253 (54.5%) < 0.001
β-blockers, n (%) 446 (24.9) 88 (19.1%) 107 (24.2%) 101 (23.7%) 150 (32.3%) < 0.001
Hg, g/dL 12.8 ± 2.0 13.7 ± 1.9 13.5 ± 1.8 12.7 ± 1.8 11.6 ± 1.7 < 0.001
Albumin, g/dL 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.1 ± 0.5 < 0.001
TC, mg/dL 173.7 ± 39.1 171.6 ± 36.0 172.4 ± 41.8 175.2 ± 38.0 175.5 ± 40.5 0.082
hsCRP, mg/L� 0.6 (0.2–1.6) 0.6 (0.2–1.7) 0.6 (0.3–1.7) 0.6 (0.2–1.5) 0.6 (0.2–1.7) 0.620
Ca, mg/dL 9.1 ± 0.5 9.1 ± 0.5 9.2 ± 0.4 9.2 ± 0.5 9.0 ± 0.7 < 0.001
P, mg/dL 3.7 ± 0.7 2.9 ± 0.3 3.5 ± 0.1 3.8 ± 0.1 4.5 ± 0.5 < 0.001
25D, ng/mL 18.1 ± 10.1 19.9 ± 11.2 19.0 ± 9.6 17.7 ± 10.1 15.8 ± 8.8 < 0.001
1,25D, pg/mL 31.6 ± 16.8 34.6 ± 16.7 33.5 ± 16.3 30.6 ± 17.9 27.5 ± 15.3 < 0.001
PTH, pg/mL 75.1 ± 77.7 61.2 ± 59.1 56.5 ± 39.7 66.0 ± 56.7 113.8 ± 114.1 < 0.001
FGF23, RU/mL� 19.7 (1.6–34.7) 12.2 (0.5–28.8) 18.6 (1.1–31.7) 19.9 (3.9–33.4) 26.9 (5.4–48.7) < 0.001
Klotho, pg/mL� 535.0 (420.0–667.0) 545.5 (441.5–687.0) 559.0 (420.0–689.5) 530.0 (424.0–664.0) 503.0 (392.5–625.5) 0.001
FGF23/Klotho, RU/ng� 33.8 (2.8–73.2) 22.1 (0.9–56.9) 31.6 (2.2–61.5) 34.7 (7.4–70.4) 53.6 (10.2–111.8) < 0.001
FEP, % 19.6 ± 11.9 17.6 ± 10.1 18.0 ± 10.6 17.7 ± 10.8 24.7 ± 14.2 < 0.001
DPI, g/kg/day� 0.9 (0.8–1.1) 1.0 (0.8–1.2) 1.0 (0.8–1.2) 0.9 (0.8–1.1) 0.9 (0.7–1.1) < 0.001
24hr EP, mg/day� 570.4 (400.0–744.8) 600.0 (456.6–800.0) 600.0 (400.0–800.0) 552.2 (400.0–743.2) 500.0 (400.0–685.0) < 0.001
24hr EP/GFR, mg/day/
GFR�
12.3 (7.3–20.6) 10.5 (7.0–16.3) 10.9 (6.6–17.1) 11.6 (7.2–19.2) 18.1 (10.0–30.9) < 0.001
24hr TRP, mg/day� 1689.0 (899.0–
2967.8)
1693.2 (1003.4–2730.4) 1999.6 (1143.4–3214.1) 1946.0 (1007.9–3644.8) 1252.5 (544.6–2477.5) < 0.001
24hr TRP/GFR, mg/day/
GFR�
38.7 (29.7–45.7) 30.9 (24.7–36.0) 38.8 (33.3–43.1) 43.7 (35.8–48.1) 45.8 (35.7–53.5) < 0.001
�Data are expressed as median and interquartile range, and compared using the Kruskal-Wallis test.
BMI: body mass index; DM: diabetes mellitus; HTN: hypertension; CVD: cardiovascular disease; CCI: Charlson comorbidity index, GFR: estimated glomerular filtration
rate by CKD-EPI formula; 24hr UPE: 24hr urine protein; RAAS: renin-angiotensin-aldosterone system; CCB: calcium channel blocker; Hg: hemoglobin; TC: total
cholesterol; hsCRP: highly sensitive C-reactive protein; Ca: calcium; P: phosphate; 1,25D: 1,25-(OH)2-vitamin D3; 25D: 25-(OH)-vitamin D3; PTH: parathyroid
hormone; FGF23: fibroblast growth factor23; FEP: fractional excretion of phosphate; DPI: estimated daily protein intake; 24hr EP/GFR: 24hr urinary phosphate
excretion rate of phosphate to glomerular filtration rate; 24hr TRP/GFR; 24hr tubular reabsorption of phosphate to glomerular filtration rate
https://doi.org/10.1371/journal.pone.0235077.t001
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Mediation analysis results
We first performed simple mediation analyses with the FGF23 and klotho levels, FGF23/klotho
ratio, FEP, and 24-h EP/GFR. Table 3 shows all path coefficients obtained in the simple media-
tor model. The FGF23 level (effect size, 0.006; 95% CI, 0.001 to 0.014) and the 24-h EP/GFR
(effect size, 0.023; 95% CI, 0.008 to 0.038) partially mediated the effect of proteinuria on the
serum phosphate level, whereas the klotho level (effect size, 0.003; 95% CI, –0.001 to 0.008)
and FEP (effect size, –0.001; 95% CI, –0.003 to 0.002) showed no mediation effect (Table 3). In
combinatorial analyses, the FGF23/klotho ratio (effect size, 0.007; 95% CI, 0.001 to 0.015;
Table 3) exhibited the strongest mediation effect, which was greater than that of the FGF23
level alone.
We performed a second round of mediation analyses using the FGF23/klotho ratio and
24-h EP/GFR as mediators in a serial two-mediator model. Path models describing mediation
of the relationship between 24-h UPE and the serum phosphate level by the serum FGF23/
klotho ratio and 24-h EP/GFR are depicted in Fig 3. Regression Coeffs., SEs, and model sum-
mary information for the presumed influence of the two serial-mediator model are presented
in Table 4.
All indirect pathways exhibited significant relationships between variables; however, the
direct effect of the association between 24-h UPE and the serum phosphate level was signifi-
cantly attenuated, and the model was no longer significant after inclusion of the serum FGF23/
klotho ratio and 24-h EP/GFR (direct effect size, 0.017; 95% CI, –0.026 to 0.060; Fig 3).
In Fig 4, we visualize the patterns of relative direct and mediation effects between 24-h UPE
and the serum phosphate level. In the serial multiple-mediator model, the mediation effects of
the FGF23/klotho ratio and 24-h EP/GFR were 13.6% and 45.5%, respectively, of the total
effect, with an additional 2.3% contributed to the effect when these variables were used sequen-
tially. The relative indirect effect of 24-h UPE on the serum phosphate level was 38.6% of the
total in the serial two-mediator model.
Sensitivity analysis results
To further validate our findings, we performed two rounds of sensitivity analysis, excluding
patients with GFRs < 15 mL/min/1.73 m2 (n = 1599; S1 Table in S1 Data) and those with 24-h
UPEs� 3500 mg/day (n = 1520; S2 Table in S1 Data). All indirect pathways exhibited
Table 2. Univariate and adjusted associations between proteinuria (exposure) and serum phosphate level (out-
come) (n = 1701).
Model Coeff. ± SE t value P
Crude 0.153 ± 0.017 9.260 < 0.001
Model 1 0.168 ± 0.016 10.313 < 0.001
Model 2 0.114 ± 0.017 6.757 < 0.001
Model 3 0.044 ± 0.021 2.077 0.038
Model 4 0.017 ± 0.022 0.766 0.444
Model 1: adjustment for age, sex, smoking, and BMI
Model 2: model 1+adjustment for DM, HTN, and CCI
Model 3: model 2+adjustment for RAAS blockers, PTH, DPI, hsCRP and eGFR
Model 4: model 3+adjustment for FGF23/Klotho and 24hr EP/GFR.
Estimate coefficient (Coeff.) and standard Error (SE) are expressed according to increasing 24hr UPE categories
(<30, 30–300, 300–1000,�1000 mg/day).
DPI, hsCRP, FGF23, Klotho and 24hr EP/GFR have been natural log-transformed due to skewed distribution.
https://doi.org/10.1371/journal.pone.0235077.t002
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significant relationships among variables, although the direct effects of the association between
24-h UPE and the serum phosphate level were attenuated significantly after inclusion of the
serum FGF23/klotho ratio and 24-h EP/GFR (S3 and S4 Figs).
Discussion
This study presents noteworthy findings which may be useful in the pre-dialysis diagnosis of
CKD. First, the degree of proteinuria correlated strongly with the serum FGF23/klotho ratio
and 24-h EP/GFR, and these variables were related to the serum phosphate level. Second,
mediation analysis including the FGF23/klotho ratio and 24-h EP/GFR showed that the degree
of proteinuria and serum phosphate level were attenuated strongly when these factors were
Fig 1. Associations among the serum phosphate level, FGF-23/klotho ratio, 24-h EP/GFR, and 24-h TRP/GFR according to CKD stage and degree of proteinuria.
Patients with CKD exhibit higher serum phosphate levels, FGF-23/klotho ratios, and 24-h EP/GFRs and lower 24-h TRP/GFRs with increasing proteinuria. The
relationships between the CKD stage and (A) serum phosphate level, (B) FGF-23/klotho ratio, (C) 24-h TRP/GFR, and (D) 24-h EP/GFR in three 24-h UPE groups were
plotted. The central rectangles in the boxplots span the interquartile ranges. The segments inside the rectangles show the medians. Whiskers above and below the boxes
show the locations of the minimum and maximum values, which are no more than 1.5 times the interquartile ranges distant from the boxes.
https://doi.org/10.1371/journal.pone.0235077.g001
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added to the analysis. Together, these observations suggest a causal relationship between pro-
teinuria and the serum phosphate level, such that proteinuria affects the FGF23 and klotho lev-
els, resulting in an increased phosphate burden per unit nephron, irrespective of the GFR, and
elevation of the serum phosphate level.
The systemic regulation of phosphate homeostasis is controlled by a complex set of interac-
tions involving the small intestine, bone, parathyroid gland, and kidney [24, 25]. In addition,
renal phosphate regulation involves FGF23 and its co-receptor klotho, which in turn affects
the NaPi-2a concentration in the renal proximal tubule [26, 27]. Thus, phosphate excretion
increases as the GFR falls if this process is not accompanied by an influx of phosphate into the
systemic circulation, even when the FGF23 expression level is high [24, 25, 28–31]. In previous
studies, serum levels of FGF23 were elevated in pediatric patients with nephrotic-range pro-
teinuria and in patients with IgA nephropathy and proteinuria [8, 9]. We also demonstrated
Fig 2. Composite relationships to 24-h UPE, the FGF23/klotho ratio, and the GFR. (A) The composite figure shows that the FGF23/klotho ratio, 24-h EP/GFR, and
serum phosphate level increase steadily with the 24-h UPE, while the 24-h TRP/GFR decreases steadily. (B) The 24-h UPE, 24-h EP/GFR, and serum phosphate level
increase steadily with the FGF23/klotho ratio as the GFR and 24-h TRP/GFR decrease steadily. (C) As the GFR decreases, the 24-h TRP/GFR decreases gradually. This
effect is seen earlier in patients with severe proteinuria. (D) As the GFR decreases, the 24-h EP/GFR increases significantly. This increase occurs more rapidly in patients
with severe proteinuria.
https://doi.org/10.1371/journal.pone.0235077.g002
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that the 24-h UPE and FGF23 level tended to increase and the klotho level tended to decrease
in patients with higher serum phosphate levels.
When the GFR and proteinuria were considered together with the serum phosphate level,
the 24-h TRP/GFR was found to decrease and the 24-h EP/GFR was found to increase in
response to increasing proteinuria, even in patients with similar GFRs, resulting in increased
phosphate burden per unit nephron. Thus, renal activity levels can be assumed to be higher,
facilitating increased phosphate excretion, in patients with higher proteinuria relative to those
with similar renal function but less proteinuria. The 24-h UPE to creatinine clearance ratio
was shown to be associated with more rapid CKD progression, suggesting a harmful effect of
an increased phosphate burden per unit nephron prior to an increase in the serum phosphate
level [32].
Previous studies have revealed a link between proteinuria and renal klotho expression [33–
36]. In patients receiving interventions to reduce proteinuria, renal klotho expression and the
circulating α-klotho level were elevated, indicating that the expression and secretion of klotho
resulted in a decrease in proteinuria [37, 38]. In vitro studies have shown that albumin directly
reduces klotho expression in cultured tubular cells [33], and the FGF23 level has been associ-
ated with proteinuria in patients with CKD [9, 39]. Other researchers have suggested that a
reduction in proteinuria leads to a concomitant decrease in FGF23 expression, which together
Table 3. Results of simple mediation analyses.
Proteinuria (exposure) Serum phosphate (outcome)
Mediators Effect ± SE 95% CI
FGF23
c 0.044 ± 0.021 0.002–0.086
c' 0.038 ± 0.021 - 0.004–0.079
ab 0.006 ± 0.003 0.001–0.014
Klotho
c 0.044 ± 0.021 0.002–0.086
c' 0.041 ± 0.021 - 0.001–0.083
ab 0.003 ± 0.002 - 0.001–0.008
FGF23/Klotho
c 0.044 ± 0.021 0.002–0.086
c' 0.037 ± 0.021 - 0.004–0.079
ab 0.007 ± 0.004 0.001–0.015
FEP
c 0.044 ± 0.021 0.004–0.087
c' 0.045 ± 0.021 0.004–0.088
ab - 0.001 ± 0.001 - 0.003–0.002
24hr EP/GFR
c 0.044 ± 0.021 0.002–0.086
c' 0.021 ± 0.022 - 0.023–0.065
ab 0.023 ± 0.008 0.008–0.038
Covariates; age, sex, smoking, BMI, DM, HTN, CCI, RAAS blockers, PTH, DPI, hsCRP and eGFR.
Mediation effects are calculated by multiplying coefficients of path a and path b and tested for significance using a
bootstrapping (10,000 times) approach.
Estimate coefficient (Coeff.) and standard Error (SE) are expressed according to increasing 24hr UPE categories
(<30, 30–300, 300–1000,�1000 mg/day).
DPI, hsCRP, FGF23, Klotho and 24hr EP/GFR have been natural log-transformed due to skewed distribution.
https://doi.org/10.1371/journal.pone.0235077.t003
PLOS ONE Proteinuria and serum phosphate
PLOS ONE | https://doi.org/10.1371/journal.pone.0235077 June 22, 2020 9 / 16
help to protect kidney function [40]. Although phosphate has been shown to interfere with
antiproteinuric responses in patients with very-low-protein diets [17], the use of a high-phos-
phate food additive did not induce albuminuria [18]. Thus, when explaining the relationship
between proteinuria and the serum phosphate level, the assertion that that serum phosphate
elevation alone increases urinary excretion, induces tubular damage, and eventually causes
proteinuria is not reasonable. Instead, proteinuria-induced stimulation can be assumed to
affect the intestinal uptake and transcellular redistribution of phosphate, leading to an increase
in systemic influx, although further studies are necessary to confirm this hypothesis.
Fig 3. Mediation analyses of the effect of 24-h UPE on the serum phosphate level. Path models and mediation analyses describing mediation of the effect of 24-h UPE
on the serum phosphate level by the serum FGF23/klotho ratio and 24-h EP/GFR. The models were adjusted for age, sex, smoking, BMI, DM, CCI, HTN, RAAS blocker
use, PTH level, DPI, hsCRP level, and eGFR.
https://doi.org/10.1371/journal.pone.0235077.g003
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In this study, we used a mediation model to better understand the mechanism underlying
the observed relationship between proteinuria and the serum phosphate level. Our results sup-
port the influence of proteinuria on FGF23/klotho expression, indicating a direct causal rela-
tionship that ultimately affects the phosphate balance via its effects on tubular phosphate
regulation. We also examined the association between proteinuria and the serum phosphate
level after excluding patients with GFRs < 15 mL/min/1.73m2 (n = 1599; S1 Table in S1 Data)
or 24-h UPEs� 3500 mg/day. This analysis showed that the FGF23 and klotho levels and their
tubular phosphate regulation are indispensable factors in the regulation of phosphate balance,
relative to other variables that might affect the relationship between proteinuria and the serum
phosphate level. In addition, consideration of the FGF23/klotho ratio, rather than the FGF23
or klotho level alone, may be more suitable for the prediction of renal phosphate regulation, as
these factors account for the increment of phosphate burden per unit nephron in patients with
CKD and proteinuria.
To account for proteinuria-induced FGF23 resistance at the molecular level, a megalin/
cubulin system is required for endocytosis and lysosomal degradation of proximal tubule
NPT2a. This system is also used for the reabsorption of albumin. Hence, we could hypothesize
that the increased severity of proteinuria in patients with CKDF and increased FGF23/klotho
ratios results in decreased phosphate excretion due to decreased endocytosis and degradation
of NaPi via the megalin/cubulin system [41–43]. However, the 24-h TRP/GFR was inversely
proportional to the degree of proteinuria in this study, which is not consistent with this
hypothesis.
Recently, diurnal variation in the regulation of serum phosphate was reported [44, 45]. In
addition to dietary intake and renal phosphate regulation by FGF23 and PTH, the role of the
nicotinamide phosphoribosyltransferase (Nampt)/nicotinamide adenine dinucleotide (NAD+)
system on phosphate transfer in the liver, kidney, intestine, and soft tissues has been empha-
sized [44, 46]. In this study, blood samples were obtained after fasting, preventing us from con-
sidering diurnal variation in the regulation of serum phosphate. Thus, future studies should
consider the effects of serum phosphate levels at the times of measurement. In addition, the
examination of variations in phosphate distribution associated with the Nampt/NAD+ system
in patients with CKD and proteinuria is important.
In our study, FGF23 levels were measured using an ELISA kit that quantifies intact FGF23
and cFGF23. Although it is physiologically correct that intact FGF23 represents phosphaturic
activity, its use has been reported to be unfavorable due to diurnal and intraindividual
Table 4. Regression coefficients, standard errors, and model summary information for the presumed media influence of the serial multiple mediator model.
Consequent
M1 (FGF23/Klotho) M2 (24hr EP/GFR) Y (serum P)
Antecedent Coeff. SE P Coeff. SE P Coeff. SE P
X (24hr UPE) a1 0.154 0.064 < 0.001 a2 0.224 0.021 < 0.001 c’ 0.017 0.022 0.444
M1 (FGF23/Klotho) ― ― ― d21 0.029 0.010 < 0.001 b1 0.042 0.010 < 0.001
M2 (24hr EP/GFR) ― ― ― ― ― ― b2 0.091 0.031 0.003
Constant iM1 3.618 0.621 < 0.001 iM2 2.226 0.206 < 0.001 iY 3.905 0.218 < 0.001
R2 = 0.126 R2 = 0.570 R2 = 0.265
F(13, 1079) = 11.943, P < 0.001 F(14, 1078) = 102.123, P< 0.001 F(15, 1077) = 25.900, P < 0.001
Covariates; age, sex, smoking, BMI, DM, HTN, CCI, RAAS blockers, PTH, DPI, hsCRP and eGFR.
Estimate coefficient (Coeff.) and standard Error (SE) are expressed according to increasing 24hr UPE categories (<30, 30–300, 300–1000,�1000 mg/day).
DPI, hsCRP, FGF23, Klotho and 24hr EP/GFR have been natural log-transformed due to skewed distribution.
https://doi.org/10.1371/journal.pone.0235077.t004
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variations in the phosphate level [47]. In addition, only cFGF23 is detected in patients with
normal renal function, and it has been reported to correlate strongly with the serum phosphate
level. In our study, serum phosphate levels were measured based on fasting blood samples and
24-h UPE, and patients with near-normal renal function were included. For these reasons, we
determined that cFGF23 measurement was more reasonable. However, future studies should
examine interactions between FGF23 measurement methods and variables involved in serum
phosphate regulation.
Strengths of this study include the use of 24-h urine collections from a large cohort, the con-
current availability of multiple markers of mineral metabolism, and adjustment for confound-
ing factors that may affect serum phosphate levels. However, our study has several limitations.
First, due to the observational nature of the study, we could not exclude the possible effects of
residual confounding factors, such as the ability to regulate phosphate in the digestive system
or a change in this ability depending on the degree of proteinuria. Second, we did not control
Fig 4. Patterns of direct and mediating effects of 24-h UPE on the serum phosphate level. The radar plot depicts the relative direct
effect of 24-h UPE and mediating effects of the FGF23/klotho ratio and 24-h EP/GFR. The relative direct effect of 24-h UPE was
calculated as the direct effect divided by the total effect. The relative mediating effects were calculated as the mediating effects divided by
the total effect. The solid triangular regions represent the relative direct effect of 24-h UPE and mediating effects from the simple
mediation analyses, with the FGF23/klotho ratio and 24-h EP/GFR serving as single mediators. The open triangular regions represent the
relative direct effect of 24-h UPE and mediating effects from the serial multiple-mediator model, with the FGF23/klotho ratio and 24-h
EP/GFR serving as two sequential mediators.
https://doi.org/10.1371/journal.pone.0235077.g004
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for variables that could affect the independent and dependent variables, such as medication
use or dietary control of protein and phosphate. Although we performed mediation and sensi-
tivity analyses to speculate on the association between proteinuria and the serum phosphate
level, to increase the robustness of our findings, a more precisely designed controlled study is
warranted to verify and expand on the potential mechanistic link between these factors.
In summary, patients with higher serum phosphate levels were likely to have more severe
proteinuria and higher FGF23 levels, and lower klotho levels. In mediation analyses, the associ-
ation between proteinuria and the serum phosphate level was found to be mediated by the
FGF23/klotho ratio and 24-h EP/GFR. Together, these data demonstrate a causal relationship
between proteinuria and the serum phosphate level, suggesting the use of the FGF23/klotho
ratio and 24-h EP/GFR as mediation factors to provide insight into the mechanism potential
underlying this relationship. We believe that these results provide valuable insight into the
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